



**AIffinity**  
MOLECULAR DESIGN

# Enhancing Drug Discovery with Nuclear Magnetic Resonance & Artificial Intelligence

[www.aiffinity.com](http://www.aiffinity.com)

[info@aiffinity.com](mailto:info@aiffinity.com)

Purkyňova 127, 612 00 Brno-Medlánky, Czech Republic


# Nuclear Magnetic Resonance (NMR)

## Applications:

1. Protein Structure Determination
2. Conformational Dynamics Studies
3. Molecular Interaction Studies
4. Drug screening

## Challenges:

1. Technical Complexity
2. Instrumentation Cost
3. Resource Intensity
4. Protein Size Limitations




With **AI** and **Cheminformatics** we can navigate these challenges



# NMR in Drug Design

- Hit Identification and Hit-to-Lead.
- Interactions with ligands, peptides and other protein.
- Purity, solubility, and structural integrity of compounds.
- Development of targeted protein degraders, cyclic dinucleotides, macrocyclic peptides, and antibody-drug conjugates.




# Our solution: NMR-AI Integrated platform for Streamlined Target-to-Lead Process



## Virtual Screening & Hit Discovery

Finding drug candidates "hits" through experiments & computations



## Hit-to-Lead

Refining best hits to become lead drug candidates



## Structure Determination

Examining how drugs bind to the target protein

### Software under development

deepHitMiner

TRL 5

deepScaffOpt

TRL 7

4D-GRAPHS

TRL 8

### Solutions ready for market

1D NMR Screening

Outsourcing collaboration: NexMR, CH




Docker Image



# 1D NMR Screening

- No assay development.
- Independent of Protein 3D structure
- Gives the atoms of the small molecule that interact with the protein (**ligand epitope**)
- We develop both **Generative AI** and **Virtual Screening solutions** incorporating ligand epitope information.





# Joint Drug Development powered by our NMR-AI tech



**AIffinity**  
MOLECULAR DESIGN







**CEITEC**  
Central European Institute of Technology  
BRNO | CZECH REPUBLIC

**NEXMR**

**安宏生醫**  
AnHorn Medicines  
Innovation · New Therapeutics

**MUNI** Department of Chemistry  
**SCI**

Indication	Target	Drug type	Hit discovery	Hit to Lead	Lead Optimization	Pre-clinical Development
Prostate cancer	Androgen Receptor	PROTAC 				
Colorectal cancer	Epigenetic Regulator	Small mol. 				



**AIffinity**  
MOLECULAR DESIGN

[www.aiffinity.com](http://www.aiffinity.com)

[info@aiffinity.com](mailto:info@aiffinity.com)

Purkyňova 127, 612 00 Brno-Medlánky, Czech Republic

# AI|ffinity Team



**Thomas Evangelidis,**  
**M.Res., M.Phil., Ph.D.**  
Founder, Chief Executive Officer  
& Chief Technology Officer



**Lukasz Kozackiewicz,**  
**M.Sc., Ph.D., M.Eng.**  
Computational Biology Software Developer



**Martina Poukarová,**  
**M.BA.**  
Grant & HR manager



**Marcela Mádlíková,**  
**M.Sc.**  
Protein Biochemist



**Vaclav Hanzl,**  
**M.Eng., Ph.D.**  
Chief Software Engineer




**Íñigo Alcalde,**  
**M.Sc., Ph.D.**  
Computational Biophysics  
Software Developer



**Jakub Jakubec,**  
**M.Sc.**  
PhD Student



**Tereza Vučková,**  
**M.Sc.**  
Protein Biochemist



**Alzbeta Tuerkova,**  
**M.Sc., Ph.D., M.BA.**  
Operations & Development Manager



**Ekaterina Burakova,**  
**M.Sc., Ph.D.**  
NMR & Data Scientist



**Khanh Nguyễn Tấn,**  
**M.Sc.**  
PhD Student



**AIffinity**  
MOLECULAR DESIGN

# Open Position in Prague or Brno

## Cheminformatics Developer

<https://www.linkedin.com/jobs/view/4015443235>

**AIffinity s.r.o.**  
IČO 11992719  
Purkyňova 127,  
612 00 Brno-Medlánky,  
Czech Republic

[www.aiffinity.com](http://www.aiffinity.com)

[info@aiffinity.com](mailto:info@aiffinity.com)